Literature DB >> 32738702

Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis.

Gabriel Bsteh1, Harald Hegen2, Patrick Altmann3, Michael Auer2, Klaus Berek2, Anne Zinganell2, Franziska Di Pauli2, Paulus Rommer3, Florian Deisenhammer2, Fritz Leutmezer3, Thomas Berger3.   

Abstract

OBJECTIVE: To examine and validate thresholds for inter-eye differences in peripapillary retinal nerve fibre (pRNFL) and ganglion cell + inner plexiform layer (GCIPL) thicknesses for identifying unilateral optic neuritis in MS.
METHODS: In this two-centre, cross-sectional study, optical coherence tomography was performed in 340 patients with clinically isolated syndrome (CIS) and MS. Cut-off values of inter-eye difference for identification of eyes with a history of unilateral ON were evaluated by receiver-operating characteristics analysis.
RESULTS: For pRNFL ≥5 µm, sensitivity was 69% and specificity 68%, while for GCIPL ≥4 µm sensitivity was 67% and specificity 78%. The areas under the curve (AUC) were 0.72 (95% confidence interval: 0.64 - 0.79) for pRNFL and 0.78 (95%CI: 0.72 - 0.85) for GCIPL, indicating GCIPL as the superior model (p<0.001). When analysing only CIS patients, GCIPL inter-eye difference ≥4 µm also remained significant, while pRNFL inter-eye difference did not. INTERPRETATIONS: Inter-eye differences of ≥4 μm for GCIPL and to a lesser degree ≥5 μm for RNFL are robust thresholds for identifying unilateral optic nerve lesions. These thresholds could be used to demonstrate previous symptomatic and possibly asymptomatic ON and might be included into a new version of the diagnostic criteria.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Inter-eye difference; Multiple sclerosis; Optic neuritis; Optical coherence tomography

Mesh:

Year:  2020        PMID: 32738702     DOI: 10.1016/j.msard.2020.102403

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  10 in total

1.  Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report.

Authors:  Giorgia T Maniscalco; Lia Allegorico; Maria Elena Di Battista; Mario Annunziata; Simona Salvatore; Valentino Manzo
Journal:  Neurol Sci       Date:  2021-06-25       Impact factor: 3.307

2.  Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects.

Authors:  Elisabeth Olbert; Walter Struhal
Journal:  Wien Med Wochenschr       Date:  2022-03-28

3.  Optical Coherence Tomography and Optical Coherence Tomography Angiography Findings After Optic Neuritis in Multiple Sclerosis.

Authors:  Olwen C Murphy; Grigorios Kalaitzidis; Eleni Vasileiou; Angeliki G Filippatou; Jeffrey Lambe; Henrik Ehrhardt; Nicole Pellegrini; Elias S Sotirchos; Nicholas J Luciano; Yihao Liu; Kathryn C Fitzgerald; Jerry L Prince; Peter A Calabresi; Shiv Saidha
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003

4.  Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort.

Authors:  Natascha Schurz; Lydia Sariaslani; Patrick Altmann; Fritz Leutmezer; Christoph Mitsch; Berthold Pemp; Paulus Rommer; Tobias Zrzavy; Thomas Berger; Gabriel Bsteh
Journal:  Eye Brain       Date:  2021-03-12

5.  Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis.

Authors:  Alexandr Klistorner; Samuel Klistorner; Yuyi You; Stuart L Graham; Con Yiannikas; John Parratt; Michael Barnett
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-03-03

6.  Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis.

Authors:  Gabriel Bsteh; Harald Hegen; Patrick Altmann; Michael Auer; Klaus Berek; Franziska Di Pauli; Fritz Leutmezer; Paulus Rommer; Sebastian Wurth; Anne Zinganell; Tobias Zrzavy; Florian Deisenhammer; Thomas Berger
Journal:  Eur J Neurol       Date:  2021-04-02       Impact factor: 6.089

7.  Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis.

Authors:  Gabriel Bsteh; Harald Hegen; Patrick Altmann; Michael Auer; Klaus Berek; Franziska Di Pauli; Sebastian Wurth; Anne Zinganell; Paulus Rommer; Florian Deisenhammer; Fritz Leutmezer; Thomas Berger
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-10-29

8.  Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.

Authors:  Tobias Monschein; Sabine Salhofer-Polanyi; Patrick Altmann; Tobias Zrzavy; Assunta Dal-Bianco; Gabriel Bsteh; Paulus Rommer; Thomas Berger; Fritz Leutmezer
Journal:  J Neurol       Date:  2020-09-14       Impact factor: 4.849

9.  Retinal and Choriocapillary Vascular Changes in Early Stages of Multiple Sclerosis: A Prospective Study.

Authors:  Daniela Montorio; Roberta Lanzillo; Antonio Carotenuto; Maria Petracca; Marcello Moccia; Chiara Criscuolo; Antonio Luca Spiezia; Anna Lamberti; Federico Perrotta; Giuseppe Pontillo; Gilda Cennamo; Vincenzo Brescia Morra
Journal:  J Clin Med       Date:  2021-12-09       Impact factor: 4.241

10.  Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis.

Authors:  Nik Krajnc; Patrick Altmann; Katharina Riedl; Christoph Mitsch; Thomas Berger; Fritz Leutmezer; Paulus Rommer; Berthold Pemp; Gabriel Bsteh
Journal:  Front Neurol       Date:  2022-03-07       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.